Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tadalafil for BPH and ED
NCT01937871Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2013
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tadalafil in benign prostatic hyperplasia (BPH) and erectile dysfunction (ED) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: International Prostate Symptom Score at 12 weeks. Started Sep 2013; status: completed.
02
Drugs
tadalafil
03
Conditions
benign prostatic hyperplasia (BPH)erectile dysfunction (ED)
Beyond the preview
Go deeper on NCT01937871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01937871.